Randomized Phase II Study of Everolimus Alone Versus Everolimus Plus Bevacizumab in Patients with Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors
This randomized phase II trial studies how well everolimus and octreotide acetate with or
without bevacizumab works in treating patients with pancreatic neuroendocrine tumors that
cannot be removed by surgery and have spread nearby or to other places in the body.
Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for
cell growth. Octreotide acetate may interfere with and slow the growth of tumor cells.
Monoclonal antibodies, such as bevacizumab, may interfere with the ability of tumor cells to
grow and spread. Bevacizumab and everolimus also may stop the growth of pancreatic
neuroendocrine tumors by blocking blood flow to the tumor. It is not yet known whether
giving everolimus and octreotide acetate together is more effective with or without
bevacizumab in treating pancreatic neuroendocrine tumors.
View more details from ClinicalTrials.gov.
For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:
Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.